Results 111 to 120 of about 393,042 (353)
Cell Metabolism, 2016 Summary The discovery of brown adipose tissue (BAT) in adult humans presents a new therapeutic target for metabolic disease; however, little is known about the regulation of human BAT.
L. Ramage +9 more
semanticscholar +1 more source
IL-1α and TNF-α Down-Regulate CRH Receptor-2 mRNA Expression in the Mouse Heart [PDF]
, 2001 Two receptors (CRH receptor type 1 and CRH receptor type 2) have been identified for the stress-induced neuropeptide, CRH and related peptides, urocortin, and urocortin II.
Coste, Sarah C. +4 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie +3 more
wiley +1 more source
New dimension of glucocorticoids in cancer treatment.
Steroids, 2016 Glucocorticoids have been used in clinical oncology for over half a century. The clinical applications of glucocorticoids in oncology are mainly dependent on their pro-apoptotic action to treat lymphoproliferative disorders, and also on alleviating side ...
Kai-Ti Lin, Lu‐Hai Wang
semanticscholar +1 more source
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]
, 2006 BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Ale Algra +14 more
core +4 more sources
Rheumatologic Manifestations of Patients With Type B Insulin Resistance
Arthritis Care &Research, EarlyView.Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya +4 more
wiley +1 more source
Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments [PDF]
, 2016 Although adverse effects and glucocorticoid resistance cripple their chronic use, glucocorticoids form the mainstay therapy for acute and chronic inflammatory disorders, and play an important role in treatment protocols of both lymphoid malignancies and ...
Beck, Ilse +5 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper +7 more
wiley +1 more source
PLoS Medicine, 2016 Background Little is known about the relative risk of common bacterial, viral, fungal, and parasitic infections in the general population of individuals exposed to systemic glucocorticoids, or about the impact of glucocorticoid exposure duration and ...
L. Fardet, I. Petersen, I. Nazareth
semanticscholar +1 more source
Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases [PDF]
, 2004 Fluticasone propionate - the first carbothioate corticosteroid - has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of ...
Atsuta J +33 more
core +1 more source